CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.
June 1st 2024
An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.
FDA Approves Biosimilar Ruxience: Here's What You Need to Know
July 24th 2019With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
Breast Implant-Associated Lymphoma: Do I Need to be Concerned?
June 27th 2019Women who undergo a mastectomy have many options and concerns to consider when undergoing breast reconstruction. My choice was simple: I wanted to look as natural as possible, but I have since learned that I have textured implants.
FDA Grants Polivy Accelerated Approval for DLBCL
June 10th 2019The FDA has granted an accelerated approval to Polivy for use in combination with bendamustine and Rituxan for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.
Survey Shows Split Between Blood Cancer Detection: Symptom Evaluation vs. Incidental Finding
April 30th 2019Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.
FDA Grants Priority Review to Revlimid Plus Rituxan for Indolent Non-Hodgkin Lymphoma
February 27th 2019The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.
FDA Grants Priority Review to Antibody Drug Conjugate for Diffuse Large B-Cell Lymphoma
February 19th 2019The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).